Abstract

As with other pharma companies, we maintain production QSAR models of ADMET end points and update them regularly. Here, for six ADMET end points, we examine the predictions of test set molecules on multiple versions of random forest models spanning a period of 10 years. For any given end point, the predictions for the majority of molecules are similar for all model versions. However, for a small minority of molecules, the prediction shifts substantially over the span of a few versions. For most molecules that shift, the prediction becomes more accurate at later times. This Perspective investigates metrics that can help indicate which molecules will shift substantially in prediction and when the shift will occur.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call